ArticleBiosensors2026
A Hybrid Closed-Loop Blood Glucose Control Algorithm with a Safety Limiter Based on Deep Reinforcement Learning and Model Predictive Control.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trustworthy AI for personalized glycemic control: a systematic review and critical appraisal of multimodal forecasting and safety-critical closed-loop control.Reviews in endocrine & metabolic disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the complexity of blood glucose dynamics and the high variability of the physiological structure of diabetic patients, implementing a safe and effective insulin dosage control algorithm to keep the blood glucose of diabetic patients within the normal range (70-180 mg/dL) is currently a challenging task in the field of diabetes treatment. Deep reinforcement learning (DRL) has proven its potential in diabetes treatment in previous work, thanks to its strong advantages in solving complex dynamic and uncertain problems. It can address the challenges faced by traditional control algorithms, such as the need for patients to manually estimate carbohydrate intake before meals, the requirement to establish complex dynamic models, and the need for professional prior knowledge. However, reinforcement learning is essentially a highly exploratory trial-and-error learning strategy, which is contrary to the high-safety requirements of clinical practice. Therefore, achieving safer control has always been a major challenge for the clinical application of DRL. This paper addresses this challenge by combining the advantages of DRL and the traditional control algorithm-model predictive control (MPC). Specifically, by using the blood glucose and insulin data generated during the interaction between DRL and patients in the learning process to learn a blood glucose prediction model, the problem of MPC needing to establish a patient's blood glucose dynamic model is solved. Then, MPC is used for forward-looking prediction and simulation of blood glucose, and a safety controller is introduced to avoid unsafe actions, thus restricting DRL control to a safer range. Experiments on the UVA/Padova glucose kinetics simulator approved by the US Food and Drug Administration (FDA) show that the time proportion of adult patients within the healthy blood glucose range under the control of the model proposed in this paper reaches 72.51%, an increase of 2.54% compared with the baseline model, and the proportion of severe hyperglycemia and hypoglycemia events is not increased, taking an important step towards the safe control of blood glucose.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.